+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of Epstein-Barr virus -associated lymphomas and PTLD using Arginine Butyrate to induce viral TK gene expression Initial findings of a phase I/II trial



Treatment of Epstein-Barr virus -associated lymphomas and PTLD using Arginine Butyrate to induce viral TK gene expression Initial findings of a phase I/II trial



Blood 94(10 SUPPL 1 PART 1): 523a, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035980399

Download citation: RISBibTeXText


Related references

Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus -associated lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting (41): 544, 2000

Phase I/II trial of Arginine Butyrate and ganciclovir in Epstein-Barr virus-associated lymphoid malignancies. Journal of Clinical Oncology 24(18_suppl): 7542-7542, 2016

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109(6): 2571-2578, 2006

Arginine butyrate-induced susceptibility to ganciclovir in Epstein-Barr virus -associated lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 411-412, 1996

A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. American Journal of Pathology 140(6): 1315-1325, 1992

Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transplant Infectious Disease 3(3): 177-185, 2001

Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. Journal of Clinical Oncology 11(9): 1674-1681, 1993

Development of cell systems to study viral gene transcription at the initial phase of Epstein-Barr virus infection. Virus Genes 1(1): 73-82, 1987

Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV. European Journal of Haematology 85(3): 227-230, 2010

Restricted expression of latency-associated viral genes and production of viral IL-10 in Epstein-Barr virus-related NK/T-cell lymphomas. Journal of Dermatological Science 23(3): 198, 2000

T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. New England Journal of Medicine 318(12): 733-741, 1988

Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Human Gene Therapy 9(8): 1131-1141, 1998

Viral genotypes and p53 expression in Epstein-Barr virus-associated primary malignant lymphomas of the intestines. Human Pathology 30(10): 1146-1152, 1999

Treatment for Epstein-Barr virus-associated PTLD. Herpes 15(3): 64-67, 2009

The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. British Journal of Cancer 84(7): 920-925, 2001